Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Results available

Effect of Galantamine on Short-term Abstinence

NCT01669538
Conditions
Tobacco Use Disorder
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Individual Differences in Drug Response

NCT03809546
Conditions
Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Interventions
Dronabinol, dextrose
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Developing a Mobile Method to Measure THC-induced Impairment

NCT03804840
Conditions
Measuring THC-induced Cognitive Impairment Using a Mobile Application
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 2 Interventional Results available

Effect of Galantamine on Inflammation and Cognition

NCT03384784
Conditions
HIV Associated Cognitive Motor Complex
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Active, not recruiting Not applicable Interventional

Study to Evaluate the Safety and Effectiveness of GP0116

NCT05987163
Conditions
Skin Manifestations
Interventions
GP0116, Active Comparator: FDA approved dermal filler device (RHA 3)
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Santa Monica, California • Vista, California • Westport, Connecticut + 14 more
Conditions
Muscular Dystrophy, Duchenne
Interventions
Pentoxifylline
Drug
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
7 Years and older · Male only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Rochester, Minnesota • St Louis, Missouri + 2 more
Conditions
Chronic Kidney Diseases, Metabolic Acidosis, Fatigue, Physical Endurance, Insulin Resistance, Mitochondrial Energetics, Diabetes
Interventions
Sodium bicarbonate, placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Sacramento, California • Nashville, Tennessee
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
RBX7455, Placebo
Biological
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jefferson, Louisiana
Conditions
Knee Osteoarthritis (Knee OA), Chronic Pain, Chronic Knee Pain
Interventions
Duloxetine, Placebo
Drug
Lead sponsor
Benedict Alter
Other
Eligibility
45 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Adult HMO Supplementation and the Gut Microbiome

NCT06570330
Conditions
Healthy Adults
Interventions
SuperHMO, Non-GMO corn Maltodextrin, Rapid Absorption
Dietary Supplement
Lead sponsor
Seeding Inc
Industry
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rockville, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination Facial Aesthetic Treatment in Millennials

NCT04755595
Conditions
Dermatological Non-Disease
Interventions
Botox Cosmetic Injectable Product, Juvéderm Voluma XC, Juvéderm Volbella XC
Drug · Device
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
24 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, New York
Enrolling by invitation No phase listed Observational

INDUCE: A Prospective 2-Year Spine Registry

NCT06971835
Conditions
Subjects Treated With NMP as Part of Their Spine Surgery, Degenerative Disc Disease (DDD)
Interventions
NMP
Device
Lead sponsor
Red Rock Regeneration Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Shreveport, Louisiana • Salt Lake City, Utah
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA®4 for Midface Volume Deficiency

NCT05133739
Conditions
Cheek Augmentation, Correction of Age-related Midface Contour Deficiencies
Interventions
injection of RHA®4 in Midface, injection of Comparator Product in Midface
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Conditions
Spinal Fractures
Interventions
Percutaneous Vertebral Augmentation of compression fractures
Device
Lead sponsor
Orthovita d/b/a Stryker
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
18
States / cities
Scottsdale, Arizona • Encinitas, California • Rancho Mirage, California + 14 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS)

NCT06378086
Conditions
Pain, Aging
Interventions
RHA® Redensity with new anesthetic agent, RHA® Redensity with lidocaine
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Birmingham, Alabama • New York, New York
Conditions
Subjects Requesting and Requiring Facial Rejuvenation With Neurotoxins and/or Hyaluronic Acid Fillers
Interventions
NuDerm® System, Placebo
Other
Lead sponsor
DeNova Research
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting Phase 2 Interventional Accepts healthy volunteers

Feasibility Study for Fibroblast Autologous Skin Grafts

NCT01964859
Conditions
Wounds and Injuries
Interventions
autologous skin fibroblasts, Filler Product
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Research Investigating Drug Effects-2 (RiDE-2)

NCT06758596
Conditions
Cannabis Use, Substance Use Disorder (SUD), Healthy
Interventions
Placebo Oral Capsule, THC
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 21 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA® 3 Versus Restylane-L® for Lip Augmentation

NCT04540913
Conditions
Lip Augmentation, Lip
Interventions
RHA 3, Restylane-L
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Conditions
Kidney Injury, Acute
Interventions
Sodium Nitrate, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
canagliflozin, Placebo (for canagliflozin)
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
20 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Photoaging
Interventions
Restylane-L, Vehicle
Device
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Recruiting Phase 2 Interventional Accepts healthy volunteers

Dronabinol as an Adjunct for Reducing Pain

NCT06454669
Conditions
Low Back Pain, Chronic Pain, Back Injuries
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Christopher D. Verrico
Other
Eligibility
18 Years to 64 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Completed Not applicable Interventional Accepts healthy volunteers Results available

Gene Expression Study Between Two Dermal Injectables Hydroxylapatite Semi-permanent Filler

NCT05620043
Conditions
Gene Expression
Interventions
Sculptra, Radiesse Plus
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Miami, Florida